Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to -$4.7 million.

  • GeneDx Holdings' Cash from Investing Activities rose 3956.16% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.0 million, marking a year-over-year decrease of 4782.03%. This contributed to the annual value of -$30.1 million for FY2024, which is 3108.91% up from last year.
  • Latest data reveals that GeneDx Holdings reported Cash from Investing Activities of -$4.7 million as of Q3 2025, which was up 3956.16% from -$36.4 million recorded in Q2 2025.
  • GeneDx Holdings' 5-year Cash from Investing Activities high stood at $843000.0 for Q1 2024, and its period low was -$130.3 million during Q2 2022.
  • Its 5-year average for Cash from Investing Activities is -$15.1 million, with a median of -$4.9 million in 2023.
  • Per our database at Business Quant, GeneDx Holdings' Cash from Investing Activities tumbled by 280776.61% in 2022 and then skyrocketed by 28246.75% in 2024.
  • Over the past 5 years, GeneDx Holdings' Cash from Investing Activities (Quarter) stood at -$7.7 million in 2021, then soared by 63.11% to -$2.8 million in 2022, then plummeted by 71.39% to -$4.9 million in 2023, then surged by 89.33% to -$519000.0 in 2024, then crashed by 803.08% to -$4.7 million in 2025.
  • Its Cash from Investing Activities stands at -$4.7 million for Q3 2025, versus -$36.4 million for Q2 2025 and -$9.4 million for Q1 2025.